Mouse model | Vector | Promoter | Dosage per mouse | Route of administration | Age at treatment | Effect | Reference | |
---|---|---|---|---|---|---|---|---|
CNS | P | |||||||
Viral gene therapy | ||||||||
Npc1nih/nih Npc1nmf164 | AAV9 | GAPDH PGK NPC1 CBA hSYN1 SYN-S SYN-D CAG | 1.5 × 1011 vg | Intracerebroventricular injection | PN 0–1 | + | n.a. | [16] |
BALB/cNctr-Npc1m1N/J | AAV9 and AAV-PHP.B | EF1α | 1.84 × 1012 vg AAV9 1.43 × 1012 vg AAV-PHP.B | Retro-orbital injection | PN 24–27 | + | + | [11] |
FVB.C-Npc1m1N/J | AAV9/3 | CMV | 1.35 × 1011 vg | Intracerebroventricular and intracisternal injections | PN 4–5 | + | + | [12] |
BALB/cNctr-Npc1m1N/J | AAV9 | hSYN1 | 4.6 × 109 vg or 2.5 × 1011 vg | Bilateral intra-cerebroventricular injections | PN 0–1 | + | − | [15] |
Npc2tm1Plob | AAVrh.10 | CAG | 1011 vg | Intracisternal injection | 6 weeks | + | + | [14] |
BALB/cNctr-Npc1m1N/J | AAV9 | CMV | 2.5 × 1011 vg | Intracardiac injection | PN 4 | + | + | [13] |
BALB/cNctr-Npc1m1N/J | AAV9 | CamKII or EF1α | 2.6 × 1011 vg (neonates) 1.3 × 1012 vg (juvenile) | Retro-orbital injection | PN 1–3 PN 20–25 | + | + | [10] |
Non-viral gene therapy | ||||||||
BALB/cNctr-Npc1m1N/J | TfRMAb targeted THLs | PDGFB | 6 µg plasmid DNA and 15 µg TfRMAb | Tail-vein injection | 6–7 weeks | − | + | [22] |